
Christopher Dockendorff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4355324/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rhodium-Catalyzed Asymmetric Ring Opening of Oxabicyclic Alkenes with Organoboronic Acids. Organic Letters, 2002, 4, 1311-1314.	4.6	218
2	Applications of Multicomponent Reactions for the Synthesis of Diverse Heterocyclic Scaffolds. Organic Letters, 2007, 9, 4223-4226.	4.6	171
3	Cytoprotective activated protein C averts Nlrp3 inflammasome–induced ischemia-reperfusion injury via mTORC1 inhibition. Blood, 2017, 130, 2664-2677.	1.4	125
4	Synthesis of Dihydronaphthalenes via Aryne Dielsâ^'Alder Reactions:Â Scope and Diastereoselectivity. Journal of the American Chemical Society, 2005, 127, 15028-15029.	13.7	116
5	Palladium(II) Catalyst Systems for the Addition of Boronic Acids to Bicyclic Alkenes:  New Scope and Reactivity. Organic Letters, 2003, 5, 3695-3698.	4.6	111
6	Rhodium-Catalyzed Asymmetric Allylic Substitution with Boronic Acid Nucleophiles. Organic Letters, 2006, 8, 4569-4572.	4.6	91
7	Synthesis of diverse heterocyclic scaffolds via tandem additions to imine derivatives and ring-forming reactions. Tetrahedron, 2009, 65, 6454-6469.	1.9	79
8	Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood, 2015, 125, 1976-1985.	1.4	71
9	Concise Enantioselective Total Syntheses of (+)â€Homochelidonine, (+)â€Chelamidine, (+)â€Chelidonine, (+)â€Chelamine and (+)â€Norchelidonine by a Pd ^{II} â€Catalyzed Ringâ€Opening Strategy. Chemistry - European Journal, 2008, 14, 2112-2124.	A. 3	65
10	PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E982-E991.	7.1	55
11	Effects Of Biased PAR1 Ligands On Platelets and Endothelial Cells. Blood, 2013, 122, 23-23.	1.4	46
12	Monitoring Replication Protein A (RPA) dynamics in homologous recombination through site-specific incorporation of non-canonical amino acids. Nucleic Acids Research, 2017, 45, 9413-9426.	14.5	43
13	Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies. ACS Medicinal Chemistry Letters, 2012, 3, 808-813.	2.8	39
14	Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Medicinal Chemistry Letters, 2012, 3, 232-237.	2.8	39
15	Synthesis of Protectedl-4-[Sulfono(difluoromethyl)]phenylalanine and Its Incorporation into a Peptide. Organic Letters, 2001, 3, 1571-1574.	4.6	28
16	Discovery of μ-opioid selective ligands derived from 1-aminotetralin scaffolds made via metal-catalyzed ring-opening reactions. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1228-1232.	2.2	28
17	Overcoming fluconazole resistance in Candida albicans clinical isolates with tetracyclic indoles. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3362-3365.	2.2	21
18	Synthetic Analogues of the Snail Toxin 6-Bromo-2-mercaptotryptamine Dimer (BrMT) Reveal That Lipid Bilayer Perturbation Does Not Underlie Its Modulation of Voltage-Gated Potassium Channels. Biochemistry, 2018, 57, 2733-2743.	2.5	18

#	Article	IF	CITATIONS
19	β-Fluorofentanyls Are pH-Sensitive Mu Opioid Receptor Agonists. ACS Medicinal Chemistry Letters, 2019, 10, 1353-1356.	2.8	18
20	Benzo-fused lactams from a diversity-oriented synthesis (DOS) library as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2100-2105.	2.2	16
21	A thrombin-PAR1/2 feedback loop amplifies thromboinflammatory endothelial responses to the viral RNA analogue poly(I:C). Blood Advances, 2021, 5, 2760-2774.	5.2	15
22	Multifunctional heterocyclic scaffolds for hybrid Lewis acid/Lewis base catalysis of carbon–carbon bond formation. Tetrahedron, 2016, 72, 3905-3916.	1.9	13
23	Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells. Bioorganic and Medicinal Chemistry, 2018, 26, 2514-2529.	3.0	13
24	Identification of small-molecule inhibitors of Trypansoma cruzi replication. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7197-7200.	2.2	12
25	Indolinyl-Thiazole Based Inhibitors of Scavenger Receptor-BI (SR-BI)-Mediated Lipid Transport. ACS Medicinal Chemistry Letters, 2015, 6, 375-380.	2.8	11
26	Design and Evaluation of Heterobivalent PAR1–PAR2 Ligands as Antagonists of Calcium Mobilization. ACS Medicinal Chemistry Letters, 2019, 10, 121-126.	2.8	10
27	Discovery of bisamide-heterocycles as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2594-2598.	2.2	9
28	Synthesis of a novel bicyclic scaffold inspired by the antifungal natural product sordarin. Tetrahedron Letters, 2018, 59, 3373-3376.	1.4	9
29	The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability. Bioorganic and Medicinal Chemistry, 2019, 27, 3788-3796.	3.0	9
30	Route exploration and synthesis of the reported pyridone-based PDI inhibitor STK076545. Organic and Biomolecular Chemistry, 2020, 18, 6665-6681.	2.8	7
31	DFT-assisted design and evaluation of bifunctional copper(I) catalysts for the direct intermolecular addition of aldehydes and ketones to alkynes. Tetrahedron, 2018, 74, 4823-4836.	1.9	6
32	Design and Synthesis of Oxazoline-Based Scaffolds for Hybrid Lewis Acid/Lewis Base Catalysis of Carbon–Carbon Bond Formation. Synthesis, 2016, 48, 2413-2422.	2.3	5
33	Evaluation of α-hydroxycinnamic acids as pyruvate carboxylase inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 4041-4047.	3.0	5
34	An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126681.	2.2	5
35	Synthesis of Simplified Azasordarin Analogs as Potential Antifungal Agents. Journal of Organic Chemistry, 2019, 84, 5292-5304.	3.2	5
36	DFT-Assisted Design and Evaluation of Bifunctional Amine/Pyridine-Oxazoline Metal Catalysts for Additions of Ketones to Unactivated Alkenes and Alkynes. Synthesis, 2019, 51, 450-462.	2.3	4

#	Article	IF	CITATIONS
37	A Chemical Genetic Analysis of Platelet Activation Blood, 2009, 114, 4009-4009.	1.4	4
38	NMR Structural Analysis of Isolated Shaker Voltage-Sensing Domain in LPPG Micelles. Biophysical Journal, 2019, 117, 388-398.	0.5	3
39	A Chemical APC Mimetic Protects Endothelium from Thromboinflammatory Injury. Blood, 2016, 128, 3835-3835.	1.4	3
40	Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin αVβ3 and PAR2. RSC Medicinal Chemistry, 2020, 11, 940-949.	3.9	2
41	2-Methoxy-N-[2-(3-thienyl)-1,2,3,4-tetrahydro-1-naphthyl]acetamide. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o639-o641.	0.2	1
42	Computationallyâ€Guided Investigation of Dual Amine/pi Lewis Acid Catalysts for Direct Additions of Aldehydes and Ketones to Unactivated Alkenes and Alkynes. ChemistrySelect, 2020, 5, 8405-8414.	1.5	1
43	Modified synthesis of the peptidomimetic natriuretic peptide receptor-C antagonist M372049. Tetrahedron Letters, 2020, 61, 151654.	1.4	1
44	The Evolving Concept of Neuro-Thromboinflammation for Neurodegenerative Disorders and Neurotrauma: A Rationale for PAR1-Targeting Therapies. Biomolecules, 2021, 11, 1558.	4.0	1
45	Identification of a Novel Par1 inhibitor Using a Chemical Genetic Screen. Blood, 2010, 116, 2018-2018.	1.4	1
46	tert-Butyl (2-phenyl-1,2-dihydro-1-naphthyl)carbamate. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o107-o108.	0.2	0
47	2-(1-Phenylsulfonyl-1H-indol-3-yl)-1,2-dihydronaphthalen-1-ol. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o1030-o1032.	0.2	0
48	2,4-Dimethyl-6-phenyl-8-oxabicyclo[3.2.1]octan-3-one. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o1601-o1603.	0.2	0
49	An Allosteric Modulator of PAR1 Demonstrates Selective Inhibition of G Protein Coupling and Impairs Thrombus Formation In Vivo. Blood, 2011, 118, 1138-1138.	1.4	0
50	Discovery of Novel Small Molecule Inhibitors of Bacterial Pyruvate Carboxylase. FASEB Journal, 2018, 32, 810.15.	0.5	0